Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Natural aldose reductase inhibitor: A potential therapeutic agent for non-alcoholic fatty liver disease.

Qiu L, Guo C.

Curr Drug Targets. 2019 Oct 7. doi: 10.2174/1389450120666191007111712. [Epub ahead of print]

PMID:
31589122
2.

Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.

Qiu LX, Chen T.

World J Gastroenterol. 2015 Jan 28;21(4):1099-107. doi: 10.3748/wjg.v21.i4.1099. Review.

3.

Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor α.

Chen T, Shi D, Chen J, Yang Y, Qiu M, Wang W, Qiu L.

Mol Med Rep. 2015 Jan;11(1):303-8. doi: 10.3892/mmr.2014.2713. Epub 2014 Oct 21.

PMID:
25333350
4.

Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.

Hsu WH, Chen TH, Lee BH, Hsu YW, Pan TM.

Food Chem Toxicol. 2014 Feb;64:94-103. doi: 10.1016/j.fct.2013.11.015. Epub 2013 Nov 22.

PMID:
24275089
5.

PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.

Huang K, Du M, Tan X, Yang L, Li X, Jiang Y, Wang C, Zhang F, Zhu F, Cheng M, Yang Q, Yu L, Wang L, Huang D, Huang K.

J Hepatol. 2017 May;66(5):962-977. doi: 10.1016/j.jhep.2016.11.020. Epub 2016 Dec 12.

PMID:
27979751
6.

Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).

Sharma RS, Harrison DJ, Kisielewski D, Cassidy DM, McNeilly AD, Gallagher JR, Walsh SV, Honda T, McCrimmon RJ, Dinkova-Kostova AT, Ashford MLJ, Dillon JF, Hayes JD.

Cell Mol Gastroenterol Hepatol. 2017 Dec 13;5(3):367-398. doi: 10.1016/j.jcmgh.2017.11.016. eCollection 2018 Mar.

7.

The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in an In Vitro Model of Non-Alcoholic Fatty Liver Disease Progression.

Vecchione G, Grasselli E, Cioffi F, Baldini F, Oliveira PJ, Sardão VA, Cortese K, Lanni A, Voci A, Portincasa P, Vergani L.

Front Nutr. 2017 Sep 19;4:42. doi: 10.3389/fnut.2017.00042. eCollection 2017.

8.

Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.

Ziamajidi N, Khaghani S, Hassanzadeh G, Vardasbi S, Ahmadian S, Nowrouzi A, Ghaffari SM, Abdirad A.

Food Chem Toxicol. 2013 Aug;58:198-209. doi: 10.1016/j.fct.2013.04.018. Epub 2013 Apr 18.

PMID:
23603006
9.

Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.

Xu B, Jiang M, Chu Y, Wang W, Chen D, Li X, Zhang Z, Zhang D, Fan D, Nie Y, Shao F, Wu K, Liang J.

J Hepatol. 2018 Apr;68(4):773-782. doi: 10.1016/j.jhep.2017.11.040. Epub 2017 Dec 20.

PMID:
29273476
10.

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC.

J Gastroenterol Hepatol. 2012 Feb;27(2):341-50. doi: 10.1111/j.1440-1746.2011.06939.x.

PMID:
21929649
11.

PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.

Zhang Y, Cui Y, Wang XL, Shang X, Qi ZG, Xue J, Zhao X, Deng M, Xie ML.

Cytokine. 2015 Sep;75(1):127-35. doi: 10.1016/j.cyto.2015.05.031. Epub 2015 Jul 17.

PMID:
26194065
12.

Free radical biology for medicine: learning from nonalcoholic fatty liver disease.

Serviddio G, Bellanti F, Vendemiale G.

Free Radic Biol Med. 2013 Dec;65:952-968. doi: 10.1016/j.freeradbiomed.2013.08.174. Epub 2013 Aug 29. Review.

13.

Aldose reductase inhibitor protects mice from alcoholic steatosis by repressing saturated fatty acid biosynthesis.

Guo C, Chen L, Huang J, Wang Y, Shi C, Gao J, Hong Y, Chen T, Qiu L.

Chem Biol Interact. 2018 May 1;287:41-48. doi: 10.1016/j.cbi.2018.04.002. Epub 2018 Apr 6.

PMID:
29630881
14.
15.

Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.

Domenici FA, Brochado MJ, Martinelli Ade L, Zucoloto S, da Cunha SF, Vannucchi H.

Gene. 2013 Oct 25;529(2):326-31. doi: 10.1016/j.gene.2013.06.091. Epub 2013 Jul 24.

16.

Inhibition of aldose reductase ameliorates alcoholic liver disease by activating AMPK and modulating oxidative stress and inflammatory cytokines.

Shi C, Wang Y, Gao J, Chen S, Zhao X, Cai C, Guo C, Qiu L.

Mol Med Rep. 2017 Sep;16(3):2767-2772. doi: 10.3892/mmr.2017.6895. Epub 2017 Jun 30.

PMID:
28677809
17.

Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation.

Sun B, Jia Y, Hong J, Sun Q, Gao S, Hu Y, Zhao N, Zhao R.

J Agric Food Chem. 2018 Jul 25;66(29):7633-7642. doi: 10.1021/acs.jafc.8b01189. Epub 2018 Jul 11.

PMID:
29961332
18.

Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats.

Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE, Cicerchi C, Li N, Kuwabara M, Roncal-Jimenez CA, Johnson RJ, Lanaspa MA.

J Biol Chem. 2019 Mar 15;294(11):4272-4281. doi: 10.1074/jbc.RA118.006158. Epub 2019 Jan 16.

PMID:
30651350
19.

Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C.

Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, Vargas-Castrillón J, Lozano-Rodríguez T, Fernández-Bermejo M, Olcoz JL, González-Gallego J, García-Monzón C, Sánchez-Campos S.

Clin Sci (Lond). 2011 Mar;120(6):239-50. doi: 10.1042/CS20100387.

PMID:
20929443
20.

Aldose Reductase Inhibitors of Plant Origin in the Prevention and Treatment of Alcoholic Liver Disease: A Minireview.

Qiu L, Guo C, Hua B.

Biomed Res Int. 2019 Jun 20;2019:3808594. doi: 10.1155/2019/3808594. eCollection 2019. Review.

Supplemental Content

Support Center